AIDS buyers clubs
Executive Summary
Should be notified about the results of FDA's analysis of underground versions of Roche's Hivid (ddC), says Direct Action for Treatment Access (DATA), a California-based advocacy group. FDA said Feb. 6 that counterfeit ddC showed "potentially serious variations in product potency and quality" and told the inspected clubs to stop shipping the drug immediately. DATA says that FDA should notify uninspected buyers clubs and the general public of the potential dangers of variations in ddC potency.